According to the WHO 2022 classification [3], the term MDS/MPN with ring sideroblasts and thrombocytosis has been kept as an acceptable term to be used for cases with wild-type SF3B1 and ≥15% ring sideroblasts. This evidence concerns the gene SF3B1 and Thrombocytosis.